Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial

Previous biologic and clinical evidence has suggested that lisinopril, an angiotensin-converting enzyme inhibitor, may mitigate chemoradiation (CRT)-induced pneumonitis. We conducted a pilot, double-blind, placebo-controlled randomized trial of 23 patients with advanced non–small cell lung cancer who had concurrent fractionated CRT. They received 20 mg lisinopril or placebo daily during and 3 months after RT. Few patient-reported outcome indices showed that lisinopril was safe, and possibly beneficial, in mitigating RT-induced pulmonary distress, pending further studies.

https://ift.tt/2CYLpQE